Cargando…

Subsequent primary malignancies and acute myelogenous leukemia transformation among myelodysplastic syndrome patients treated with or without lenalidomide

The few studies that have examined rates of acute myeloid leukemia (AML) transformation in lenalidomide‐treated myelodysplastic syndrome (MDS) patients have been limited to deletion 5q MDS. The association between lenalidomide and subsequent primary malignancies (SPMs) in MDS patients has not been e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rollison, Dana E., Shain, Kenneth H., Lee, Ji‐Hyun, Hampras, Shalaka S., Fulp, William, Fisher, Kate, Al Ali, Najla H., Padron, Eric, Lancet, Jeffrey, Xu, Qiang, Olesnyckyj, Martha, Kenvin, Laurie, Knight, Robert, Dalton, William, List, Alan, Komrokji, Rami S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	Cancer Prevention
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4944897/ https://www.ncbi.nlm.nih.gov/pubmed/27098006 http://dx.doi.org/10.1002/cam4.721

Ejemplares similares

Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation
por: McDaniel, Jessica M., et al.
Publicado: (2011)

U2AF1 and EZH2 mutations are associated with nonimmune hemolytic anemia in myelodysplastic syndromes
por: Komrokji, Rami, et al.
Publicado: (2022)

Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin
por: Wang, Chen, et al.
Publicado: (2021)

Clinical utility of lenalidomide in the treatment of myelodysplastic syndromes
por: Abou Zahr, Abdallah, et al.
Publicado: (2014)

Short- and long-term benefits of lenalidomide treatment in patients with lower-risk del(5q) myelodysplastic syndromes
por: Komrokji, R. S., et al.
Publicado: (2016)

IDH mutations are enriched in myelodysplastic syndrome patients with severe neutropenia and can be a potential for targeted therapy
por: Komrokji, Rami, et al.
Publicado: (2022)

Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome
por: Komrokji, Rami S., et al.
Publicado: (2022)

Outcome of patients treated for myelodysplastic syndromes without deletion 5q after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Activity of luspatercept and ESAs combination for treatment of anemia in lower-risk myelodysplastic syndromes
por: Komrokji, Rami S., et al.
Publicado: (2023)

Outcome of patients treated for myelodysplastic syndromes with 5q deletion after failure of lenalidomide therapy
por: Prebet, Thomas, et al.
Publicado: (2017)

Cutaneous Human Papillomavirus Infection and Development of Subsequent Squamous Cell Carcinoma of the Skin
por: Hampras, Shalaka S., et al.
Publicado: (2016)

Lenalidomide Induces Lipid Raft Assembly to Enhance Erythropoietin Receptor Signaling in Myelodysplastic Syndrome Progenitors
por: McGraw, Kathy L., et al.
Publicado: (2014)

Validation of International Working Group response criteria in higher‐risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium
por: Komrokji, Rami S., et al.
Publicado: (2020)

ASXL1 frameshift mutations drive inferior outcomes in CMML without negative impact in MDS
por: Sallman, David A, et al.
Publicado: (2017)

Responses to Sars-Cov-2 Vaccines in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
por: Jain, Akriti G, et al.
Publicado: (2021)

Treatment options for lower-risk myelodysplastic syndromes. Where are we now?
por: Volpe, Virginia O., et al.
Publicado: (2021)

Naïve T-cells in Myelodysplastic Syndrome Display Intrinsic Human Telomerase Reverse Transcriptase (hTERT) Deficiency
por: Yang, Lili, et al.
Publicado: (2012)

Eprenetapopt (APR-246) and Azacitidine in TP53-Mutant Myelodysplastic Syndromes
por: Sallman, David A., et al.
Publicado: (2021)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

STATIN USE AT TIME OF RESPIRATORY VIRAL INFECTION IN PATIENTS WITH PRIOR HISTORY OF CARDIOVASCULAR DISEASE AND RISK OF SUBSEQUENT CARDIOVASCULAR EVENTS
por: Knight, Stacey, et al.
Publicado: (2015)

Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS)
por: Brunner, Andrew M., et al.
Publicado: (2022)

Myelodysplastic Syndromes with Bone Marrow Fibrosis: An Update
por: Jain, Akriti G., et al.
Publicado: (2022)

Validation of the IPSS-R in lenalidomide-treated, lower-risk myelodysplastic syndrome patients with del(5q)
por: Sekeres, M A, et al.
Publicado: (2014)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Focal blast crisis in concomitant myelodysplastic syndrome and chronic myelogenous leukemia
por: Reap, Leo, et al.
Publicado: (2020)

An Erythroid Differentiation Signature Predicts Response to Lenalidomide in Myelodysplastic Syndrome
por: Ebert, Benjamin L, et al.
Publicado: (2008)

Health-related quality of life and vulnerability among people with myelodysplastic syndromes: a US national study
por: Abel, Gregory A., et al.
Publicado: (2023)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Pulmonary Complications of Azanucleoside Therapy in Patients with Myelodysplastic Syndrome and Acute Myelogenous Leukemia
por: Molina, Manuel, et al.
Publicado: (2015)

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

Aspartate aminotransferase/alanine aminotransferase ratio and subsequent cancer development
por: Kobayashi, Daiki, et al.
Publicado: (2021)

Personalized Medicine for TP53 Mutated Myelodysplastic Syndromes and Acute Myeloid Leukemia
por: Cluzeau, Thomas, et al.
Publicado: (2021)

Characteristics of Clostridium difficile infection in patients hospitalized with myelodysplastic syndrome or acute myelogenous leukemia
por: Shah, Kamini, et al.
Publicado: (2017)

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients
por: Mangaonkar, Abhishek A., et al.
Publicado: (2022)

Efficacy of lenalidomide in myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and an extreme platelet count
por: Divoux, Marion, et al.
Publicado: (2020)

Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia
por: Karp, Judith E, et al.
Publicado: (2008)

Somatic Sequencing Identifies Trametinib-Responsive Myelodysplastic Syndrome and Finds Acquired Clonal Hematopoiesis of Indeterminate Potential
por: Vela, Cory M., et al.
Publicado: (2018)

Active immunotherapy in acute myelogenous leukaemia and the induction of second and subsequent remissions.
por: Harris, R., et al.
Publicado: (1978)

Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study
por: Posso, Margarita, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_j9j3vru5splofin7c8q20fc0rm